智通财经APP获悉，艾迪康控股(09860)盘中大涨近17%，截至发稿，涨15.58%，报4.97港元，成交额551.48万港元。
消息面上，自2025年11月艾迪康控股宣布2.04亿美元收购冠科生物后，市场担忧情绪叠加调出港股通预期，艾迪康控股股价出现调整。值得一提的是，此次短期波动，也为市场重新审视公司内在价值创造契机。3月9日，艾迪康控股退通利空出尽、资金回流有望推动股价开启估值修复。此外，冠科生物可比公司百奥赛图目前市值已达270亿港元，艾迪康当前市值明显未反映合理估值，后续修复空间充足。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.